291 related articles for article (PubMed ID: 34336101)
1. Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation.
Ramachandran S; Verma AK; Dev K; Goyal Y; Bhatt D; Alsahli MA; Rahmani AH; Almatroudi A; Almatroodi SA; Alrumaihi F; Khan NA
Oxid Med Cell Longev; 2021; 2021():5563746. PubMed ID: 34336101
[TBL] [Abstract][Full Text] [Related]
2. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics.
Srivastava S; Mohanty A; Nam A; Singhal S; Salgia R
Semin Cancer Biol; 2022 Nov; 86(Pt 2):233-246. PubMed ID: 35787939
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis.
Addison CL; Belperio JA; Burdick MD; Strieter RM
BMC Cancer; 2004 Jun; 4():28. PubMed ID: 15214968
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Derived Extracellular Vesicles Induce CCL18 Production by Mast Cells: A Possible Link to Angiogenesis.
Shefler I; Salamon P; Zitman-Gal T; Mekori YA
Cells; 2022 Jan; 11(3):. PubMed ID: 35159163
[TBL] [Abstract][Full Text] [Related]
5. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
Rice SJ; Belani CP
PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
[TBL] [Abstract][Full Text] [Related]
6. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
Zhang M; Yang W; Wang P; Deng Y; Dong YT; Liu FF; Huang R; Zhang P; Duan YQ; Liu XD; Lin D; Chu Q; Zhong B
Nat Commun; 2020 Nov; 11(1):6119. PubMed ID: 33257678
[TBL] [Abstract][Full Text] [Related]
7. Inducers, Attractors and Modulators of CD4
Xie M; Wei J; Xu J
Front Immunol; 2020; 11():676. PubMed ID: 32425930
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.
Bremnes RM; Al-Shibli K; Donnem T; Sirera R; Al-Saad S; Andersen S; Stenvold H; Camps C; Busund LT
J Thorac Oncol; 2011 Apr; 6(4):824-33. PubMed ID: 21173711
[TBL] [Abstract][Full Text] [Related]
9. The Inflammatory CXC Chemokines, GROα
Cao Y; Huang H; Wang Z; Zhang G
Immunol Invest; 2017 May; 46(4):361-374. PubMed ID: 28375674
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients.
Wang XE; Wang YH; Zhou Q; Peng M; Zhang J; Chen M; Ma LJ; Xie GM
Pathol Oncol Res; 2020 Jan; 26(1):499-505. PubMed ID: 30460541
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells.
Nazareth MR; Broderick L; Simpson-Abelson MR; Kelleher RJ; Yokota SJ; Bankert RB
J Immunol; 2007 May; 178(9):5552-62. PubMed ID: 17442937
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Integrative Analysis Reveals the Association of
Arora S; Singh P; Ahmad S; Ahmad T; Dohare R; Almatroodi SA; Alrumaihi F; Rahmani AH; Syed MA
Cells; 2021 Aug; 10(8):. PubMed ID: 34440860
[TBL] [Abstract][Full Text] [Related]
14. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Nasser MW; Elbaz M; Ahirwar DK; Ganju RK
Cancer Lett; 2015 Aug; 365(1):11-22. PubMed ID: 25963887
[TBL] [Abstract][Full Text] [Related]
15. Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.
Ge Y; Ye T; Fu S; Jiang X; Song H; Liu B; Wang G; Wang J
Front Immunol; 2023; 14():1114041. PubMed ID: 37153619
[TBL] [Abstract][Full Text] [Related]
16. Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.
Unver N
Med Oncol; 2021 May; 38(6):68. PubMed ID: 33983509
[TBL] [Abstract][Full Text] [Related]
17. Selective suppression of cytokine secretion in patients with small-cell lung cancer.
Fischer JR; Schindel M; Stein N; Lahm H; Gallati H; Krammer PH; Drings P
Ann Oncol; 1995 Nov; 6(9):921-6. PubMed ID: 8624296
[TBL] [Abstract][Full Text] [Related]
18. Chemokines and Their Receptors: Predictors of Therapeutic Potential in Tumor Microenvironment on Esophageal Cancer.
Huang CG; Liu Q; Zheng ST; Liu T; Tan YY; Peng TY; Chen J; Lu XM
Dig Dis Sci; 2024 May; 69(5):1562-1570. PubMed ID: 38580886
[TBL] [Abstract][Full Text] [Related]
19. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.
Carrega P; Loiacono F; Di Carlo E; Scaramuccia A; Mora M; Conte R; Benelli R; Spaggiari GM; Cantoni C; Campana S; Bonaccorsi I; Morandi B; Truini M; Mingari MC; Moretta L; Ferlazzo G
Nat Commun; 2015 Sep; 6():8280. PubMed ID: 26395069
[TBL] [Abstract][Full Text] [Related]
20. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.
Yang D; Zhou J; Zeng T; Yang Z; Wang X; Hu J; Song Y; Chen L; Peer D; Wang X; Bai C
Cancer Lett; 2015 Aug; 365(1):57-67. PubMed ID: 25976768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
